Nanodropper, an ophthalmic device company that makes the eyedrop volume-reducing Nanodropper Adaptor announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the adaptor compared to standard eyedrops.
The study, titled “Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor” and published in the journal Medical Devices: Evidence and Research, found that eyedrops administered with the adaptor are, on average, more than 62 percent smaller than typical drops, which are much too large for the eye.
“We know based on decades of research on microvolume delivery of eyedrops that conventional drops are too large for the eye to absorb, and that drops as small as five microliters are as efficacious as their larger counterparts,” says Jennifer Steger, PhD, CSO for Nanodropper.
“The Nanodropper bottle adaptor significantly reduces the eyedrop volume dispensed each time compared to the drops dispensed from a stock bottle, and is similarly effective across multiple medication types and bottle sizes including solutions, suspensions, or emulsions from different manufacturers,” stated Dr. Seibold, who also serves as the Director of Glaucoma Fellowship at the Sue Anschultz-Rodgers Eye Center.
The study was designed to determine the drop volume and total number of dispensed drops using the Nanodropper Adaptor, compared to drops dispensed from stock bottles “to potentially limit ocular toxicity of these eyedrops and prolong bottle use.”
According to the study, the drops delivered with the Nanodropper Adaptor were 62.1% smaller than eyedrops administered from standard bottles. This equated to 2.6-fold increase in the number of drops in a 2.5 milliliter bottle (on average, 184.1 drops with Nanodropper vs. 69.8 drops from a stock bottle).
“The ability to deliver a smaller eyedrop may help to reduce medication waste, prolong the useful life of each medication bottle, reduce cost, and as a result, may positively impact patient adherence to prescribed eyedrop therapies,” stated Dr. Seibold.
“I’m thrilled that the results of this peer-reviewed study reflect the positive impact that Nanodropper is already having on thousands of patients in reducing topical drug waste,” stated Dr. Steger.
About Nanodropper
Nanodropper is a micro-volume delivery device company offering high-value solutions to adherence barriers in chronic eye disease management. The flagship product is a patient-centered adaptor for eyedrop bottles that reduces the volume of currently oversized eyedrops by more than 60 percent. Nanodropper helps reduce cost, decrease waste, and minimize potential side effects of vision-saving treatments.
Nanodropper’s products and educational content help patients navigate issues like vision insurance, eye doctor appointments, and deploying their resources in an efficient way. These initiatives align with Nanodropper’s mission of reducing financial barriers to vision-saving medications to ultimately help patients take back control of their eye health.